DiNAQOR
DiNAQOR is a global gene therapy platform company focused on advancing novel solutions for patients suffering from heart disease. Founded in 2019, it specializes in proprietary human-based tissue drug development and technology to enable organ-specific delivery of gene therapies. The company is headquartered in Switzerland with additional presence in the US and Germany, and aims to develop gene therapy solutions that transform the lives of patients with heart disease.
Industries
Nr. of Employees
small (1-50)
Products
DiNA-001 (lead preclinical cardiac gene therapy program)
A preclinical gene therapy program targeting MYBPC3-linked hypertrophic cardiomyopathy intended to restore or correct gene function in cardiac muscle.
Proprietary Loco-Regional Perfusion (LRP) System
Delivers gene therapy directly to the heart tissue and other solid organs, limits systemic exposure, off-target effects and allows for repeat dosing.
DINAMIQS
CDMO specializing in advanced medicine production, providing GMP-compatible capabilities and scalable viral vector manufacturing.
DINA-003
Precision genetic therapy candidate for Hypertrophic Cardiomyopathy (HCM) developed as part of DiNAQOR's pipeline.
Proprietary Engineered Heart Tissue (EHT) Technology
Based on Human-induced pluripotent stem cell cardiomyocytes, EHT creates a test bed for gene therapy with rapid translation into the clinic.
DiNABIOS
Dedicated human tissue and stem cell research services company focused on advancing translational science through sophisticated engineered tissue models.
DiNA-001 (lead preclinical cardiac gene therapy program)
A preclinical gene therapy program targeting MYBPC3-linked hypertrophic cardiomyopathy intended to restore or correct gene function in cardiac muscle.
Proprietary Loco-Regional Perfusion (LRP) System
Delivers gene therapy directly to the heart tissue and other solid organs, limits systemic exposure, off-target effects and allows for repeat dosing.
DINAMIQS
CDMO specializing in advanced medicine production, providing GMP-compatible capabilities and scalable viral vector manufacturing.
DINA-003
Precision genetic therapy candidate for Hypertrophic Cardiomyopathy (HCM) developed as part of DiNAQOR's pipeline.
Proprietary Engineered Heart Tissue (EHT) Technology
Based on Human-induced pluripotent stem cell cardiomyocytes, EHT creates a test bed for gene therapy with rapid translation into the clinic.
DiNABIOS
Dedicated human tissue and stem cell research services company focused on advancing translational science through sophisticated engineered tissue models.
Services
Development and commercialization of biomanufacturing and scale-up services for viral vectors and genetic medicines to support preclinical through commercial supply.
Design, development and production services for catheter-based delivery devices intended to enable localized, loco-regional delivery of gene therapies to the heart and other organs.
Collaborative discovery and screening service to identify cardiac-targeting capsid variants using engineered heart tissue assays, capsid libraries and preclinical models.
Development and commercialization of biomanufacturing and scale-up services for viral vectors and genetic medicines to support preclinical through commercial supply.
Design, development and production services for catheter-based delivery devices intended to enable localized, loco-regional delivery of gene therapies to the heart and other organs.
Collaborative discovery and screening service to identify cardiac-targeting capsid variants using engineered heart tissue assays, capsid libraries and preclinical models.
Expertise Areas
- Cardiac gene therapy development
- Capsid engineering and vectorology
- Engineered heart tissue and iPSC disease modeling
- Catheter-based delivery systems and loco-regional perfusion
Key Technologies
- Adeno-associated virus (AAV) vectors
- Adenoviral and helper-dependent adenoviral vectors
- Capsid library screening and engineering
- Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes